About NextWave Pharmaceuticals
NextWave Pharmaceuticals is a Healthcare company based in Cupertino (United States) founded in 2005, and was acquired by Tris Pharma in September 2018. Pharmaceutical products for CNS and ADHD treatments are developed. NextWave Pharmaceuticals has raised $95 million across 3 funding rounds from investors including Pfizer, Tris Pharma and Eight Roads Ventures. The company was acqui-hired. NextWave Pharmaceuticals offers products and services including Quillivant XR. Its focus areas include Life Sciences, Neurology, Drugs and Psychiatric. Its legal entity is NEXTWAVE PHARMACEUTICALS INCORPORATED. Its competitors include Alto Neuroscience, Supernus Pharmaceuticals and Neurovance; 2 of its 3 listed competitors have raised funding.
Company details
NextWave Pharmaceuticals was founded in 2005 and is based in Cupertino, United States. Focus is placed on the development and commercialization of drugs targeting attention deficit hyperactivity disorder (ADHD) and other central nervous system (CNS) conditions. The pipeline consists of NWP06 as an oral suspension for ADHD, NWP09 as chewable tablets for ADHD, and NWP08 as clonidine extended-release chewable tablets. Operations center on pharmaceutical innovation in this sector.
- Headquarters Cupertino, United States
- Stage Acquired
- SectorsHealthcare
- Website nextwavepharma.com
- Social LinkedIn
- Acquired by Tris Pharma (Sep 2018)
- Legal Name Nextwave Pharmaceuticals Incorporated
- Total Equity Funding$95M (USD)
in 3 rounds
- Latest Funding Round$45M (USD), Series C
Jan 2011
- InvestorsPfizer
& 8 more
- Acquired by
Products & Services of NextWave Pharmaceuticals
NextWave Pharmaceuticals offers a comprehensive portfolio of products and services, including Quillivant XR.
Liquid prescription for controlling ADHD symptoms in children.
Funding Insights of NextWave Pharmaceuticals
NextWave Pharmaceuticals has successfully raised a total of $95M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $45 million completed in January 2011. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $95M
- Total Rounds 3
- Last Round Series C — $45M
- First Round $10M
(Jun 2005)
- Investors Count 7
All 3 funding rounds of NextWave Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2011 | $45M | Series C | – | Panorama Capital, Bay City Capital | |
| Feb 2007 | $40M | Series B | – | Sofinnova Investments, Vivo Capital | – |
| Jun 2005 | $10M | Series A | – | Sofinnova Investments, Vivo Capital | – |
9 investors in total: 9 institutional.
Investors in NextWave Pharmaceuticals
NextWave Pharmaceuticals has secured backing from 9 investors, including venture fund and institutional investors. Prominent investors backing the company include Pfizer, Tris Pharma and Eight Roads Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early & later stage venture capital firm investing in the US | panoramacapital.com | Campbell, United States | ||
Stage-agnostic investments in US life-sciences sectors are managed. | baycitycapital.com | San Francisco, United States | ||
Venture capital is invested in US life sciences companies. | kearnyvp.com | San Francisco, United States | ||
PE firm investing in the US | aislingcapital.com | New York, United States | ||
Biotech funding, drug development support, and investment in life sciences. | sofinnova.com | |||
Venture capital investment and global platform support for startups. | 2008 | eightroads.com | London, United Kingdom | |
Venture capital and private equity firm | vivocapital.com | Palo Alto, United States | ||
Pharmaceutical products for treating multiple diseases are provided. | 1849 | pfizer.com | New York, United States | |
Technology-based oral extended release pharmaceutical products are developed. | 2000 | trispharma.com | Monmouth Junction, United States |
Investor details for NextWave Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of NextWave Pharmaceuticals
5 dated milestones of NextWave Pharmaceuticals across 13 years, from founding to its latest funding, stage changes and deals.
- Founded NextWave Pharmaceuticals is founded.
- Funding First funding round of $10.0M.
- Funding Latest funding round, Series C, of $45.0M.
- Exit Acquired by Pfizer.
- Exit Acquired by Tris Pharma.
Competitors of NextWave Pharmaceuticals
NextWave Pharmaceuticals has 3 listed competitors in our database, 2 of them funded. They include Alto Neuroscience, Supernus Pharmaceuticals and Neurovance.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| altoneuroscience.com | 2019 | San Francisco, United States | $144.72M | 34 | AI-driven drug discovery platform for neurological diseases based on patients biomarkers | |
| supernus.com | 2005 | Rockville, United States | 652 | Specialty pharmaceutical products for CNS diseases are developed and commercialized. | ||
| neurovance.com | 2011 | Cambridge, United States | $53.03M | 7 | Neurochemical modulators for ADHD treatment are developed by Neurovance. |
Detailed competitors of NextWave Pharmaceuticals
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Neurology
3 companies that operate in the same segment as NextWave Pharmaceuticals (Neurology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Developer of therapeutics for psychiatric and neurologic diseases | 2002 | New York, New York, United States | USD 80.87 M | USD 250.31 M | 600 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about NextWave Pharmaceuticals
NextWave Pharmaceuticals was founded in 2005.
NextWave Pharmaceuticals is headquartered in Cupertino, United States. It is registered at Cupertino, California, United States.
NextWave Pharmaceuticals is a funded company, having raised a total of $95M across 3 funding rounds to date. The company's 1st funding round was a Series A of $10M, raised on Jun 2005.
NextWave Pharmaceuticals was founded in 2005 and is based in Cupertino, United States. Focus is placed on the development and commercialization of drugs targeting attention deficit hyperactivity disorder (ADHD) and other central nervous system (CNS) conditions. The pipeline consists of NWP06 as an oral suspension for ADHD, NWP09 as chewable tablets for ADHD, and NWP08 as clonidine extended-release chewable tablets. Operations center on pharmaceutical innovation in this sector.
NextWave Pharmaceuticals's top competitors include Alto Neuroscience, Supernus Pharmaceuticals and Neurovance.
NextWave Pharmaceuticals offers Quillivant XR.
NextWave Pharmaceuticals has 9 investors. Key investors include Pfizer, Tris Pharma, Eight Roads Ventures, Panorama Capital, and Bay City Capital.
NextWave Pharmaceuticals operates through Nextwave Pharmaceuticals Incorporated.
Yes. NextWave Pharmaceuticals was acquired by Tris Pharma in September 2018.